Developer docs
API playgroundTry for free, no card

Search company profiles

CLL Society

Full company profile

uuid02mbd9e

Namestring
CLL Society
Legal namestring
CLL Society Inc.
Websiteurl
cllsociety.org
Company typeenum
Private
Founded yearint
2013
Descriptiontext

CLL Society is a 501(c)(3) nonprofit organization founded in 2013 by Dr. Brian Koffman, a physician and CLL patient, and Patricia Koffman, a care partner. Headquartered in Nashville, Tennessee and operating with an 11–50 employee team, the organization provides free education, support, advocacy, and research programs for individuals affected by chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It does not develop commercial technology products; instead it curates physician-reviewed educational content, maintains clinical trial listings, and operates the CLL Medicine Cabinet — a drug information resource covering CLL/SLL therapeutics — alongside a Policy Institute for the immunocompromised community.

The organization's core service offerings include Expert Access™, a free virtual second opinion program delivered through partner Alight's HIPAA-compliant platform connecting US-based patients with world-renowned CLL experts; a Peer Support Program pairing patients one-on-one; CLL-specific support groups; the CareCast podcast; on-demand webinars; the Emotional & Spiritual Advocate Program; the Trusted Care Exchange connecting patients with healthcare providers; and the COVID-19 Resources program for immunocompromised patients. In 2026 the organization launched the CLL Treatment Decision Tool, built with Decera Clinical Education to translate input from five CLL experts into a patient-facing decision aid. The Research Grant Program, launched in 2022 and funded entirely through individual contributions, has cumulatively directed over $2,150,000 to CLL/SLL researchers through Clinical Scholar and Young Investigator Awards.

CLL Society is funded through individual donations and corporate grants/sponsorships from pharmaceutical companies organized into an Industry Advisory Council. The 2026 Council includes Platinum members AbbVie, BeiGene/BeOne, Genentech, and Lilly, and Gold members AstraZeneca and Invivyd. The organization maintains stated editorial independence from corporate donors, does not endorse specific medications, and operates free of charge to patients and caregivers. It has been recognized with a 4-star Charity Navigator rating and a Candid (GuideStar) Platinum Seal of Transparency.

Short descriptiontext

CLL Society is a 501(c)(3) nonprofit founded in 2013 that provides free education, support, advocacy, and research funding for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and their caregivers. Programs include Expert Access virtual second opinions, peer support, treatment decision tools, and a research grant program funded by individual donations and pharmaceutical sponsorships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChula Vista, United States
HQ citystring
Chula Vista
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
patient education services, cancer support programs, clinical trial information, leukemia advocacy, research grant funding
NAICS code3 codes
  • Social Advocacy Organizations8133
  • Other Individual and Family Services624190
  • Other Individual and Family Services62419
SIC code3 codes
  • Services-Social Services8300
  • Services-Educational Services8200
  • Services-Misc Health & Allied Services, Nec8090
Product category
Patient Advocacy and Support Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Individual Donations
TypeGrants Donations
Description

CLL Society is funded primarily through individual donations from patients, caregivers, and supporters of the CLL community. Donations support the organization's mission of education, advocacy, support, and research.

cllsociety.org
2Corporate Grants and Sponsorships
TypeProfessional Services
Description

CLL Society receives financial support from pharmaceutical and healthcare companies in the form of restricted and unrestricted grants and sponsorships. The organization maintains full editorial independence and does not endorse specific medications or treatments. Corporate partners include AbbVie, BeiGene/BeOne, Genentech, Lilly, AstraZeneca, and Invivyd through the Industry Advisory Council.

cllsociety.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 4 records shown
1Expert Access™
Description

A free virtual second opinion program connecting CLL patients with world-renowned CLL experts.

cllsociety.org
+3 more records
Core offering1 text field

CLL Society is a 501(c)(3) nonprofit that provides free education, support, advocacy, and research programs for patients affected by chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Its core offerings include free virtual expert second opinions (Expert Access™), one-on-one peer support, CLL-specific support groups, physician-curated educational content (CareCast Podcast, Education On-Demand webinars, Medicine Cabinet, Patient Education Toolkit), an interactive CLL Treatment Decision Tool, advocacy through its Policy Institute, and a Research Grant Program funding CLL/SLL investigators.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CLL Society is a nonprofit patient-centric, physician-curated organization providing comprehensive education, support, and research for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients. The organization offers a suite of patient support services including Expert Access™ (free virtual second opinions), Peer Support Program, Emotional & Spiritual Advocate Program, and CLL-specific support groups. Educational offerings include the CLL Medicine Cabinet (drug information), CLL/SLL Patient Education Toolkit, CareCast Podcast, and Education On-Demand webinars. The CLL Treatment Decision Tool provides algorithmic treatment recommendations based on expert input. CLL Society also funds research through its Research Grant Program and maintains clinical trial information resources.

Product and service12 records
1Expert Access™
CategoryExpert Consultation Service
Description

Free virtual second opinion consultation service connecting CLL/SLL patients in the United States with world-renowned CLL experts via HIPAA-compliant video consultations, producing expert opinions patients can share with their local treatment team.

2Peer Support Program
CategoryPeer Support Service
Description

One-on-one peer support program pairing CLL patients with trained fellow patients for emotional support and shared lived experience.

3Emotional & Spiritual Advocate Program
CategoryEmotional and Spiritual Support Service
Description

Program supporting the emotional, spiritual, and mental well-being of CLL patients and their care partners.

4Support Groups
CategoryCommunity Support Service
Description

CLL-specific patient support groups providing community connection and peer support for patients and caregivers.

5CareCast Podcast
CategoryEducational Content Service
Description

Educational podcast series providing information and updates on CLL/SLL research, treatments, and patient experiences.

6Education On-Demand
CategoryEducational Content Service
Description

On-demand educational activities and webinars for CLL patients covering treatments, research, and disease management.

7CLL Medicine Cabinet
CategoryDrug Information Resource
Description

Comprehensive resource providing detailed information on CLL medications including dosing, side effects, administration, and management guidance.

8CLL Treatment Decision Tool
CategoryInteractive Treatment Decision Resource
Description

Interactive treatment decision resource, built with Decera Clinical Education, offering personalized treatment options based on algorithmic inputs from five CLL experts through a patient-completed questionnaire.

9Research Grant Program
CategoryResearch Funding Program
Description

Research grant program funding novel projects aimed at improving outcomes and quality of life for CLL/SLL patients, having dedicated $2,150,000 to CLL/SLL researchers since 2022.

10CLL/SLL Patient Education Toolkit
CategoryPatient Education Toolkit
Description

Comprehensive educational resource covering CLL/SLL basics, testing, staging, treatment options, MRD testing, complications, and disease management tools.

11Trusted Care Exchange
CategoryCare Coordination Service
Description

Resource connecting CLL patients with healthcare providers and facilitating care coordination.

12COVID-19 Resources
CategoryImmunocompromised Patient Support Resource
Description

COVID-19 information and resources specific to CLL/SLL patients, including action plans, prevention, treatment guidance, and virtual community meetings.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CLL Society partners with Alight, an online second opinion service that uses live video technology to connect patients with top US-based medical specialists. Alight provides HIPAA-compliant platform infrastructure for the Expert Access program's virtual consultations. Eighty percent of those provided a 2nd opinion through Alight were seeking oncology consultations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CLL Society collaborated with Decera Clinical Education to create the CLL Treatment Decision Tool, offering information about common treatment options for CLL. Decera's mission is to improve clinical care and patient health outcomes through evidence-based educational activities.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Platinum member of CLL Society's 2026 Industry Advisory Council. AbbVie manufactures Imbruvica (ibrutinib) and venetoclax (Venclexta) used in CLL treatment.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Platinum member of CLL Society's 2026 Industry Advisory Council. BeiGene manufactures zanubrutinib (Brukinsa) and sonrotoclax (Beqalzi) used in CLL treatment.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Platinum member of CLL Society's 2026 Industry Advisory Council. Genentech manufactures obinutuzumab (Gazyva) used in CLL treatment.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Platinum member of CLL Society's 2026 Industry Advisory Council.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Gold member of CLL Society's 2026 Industry Advisory Council. AstraZeneca manufactures acalabrutinib (Calquence) used in CLL treatment.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Gold member of CLL Society's 2026 Industry Advisory Council. Invivyd focuses on antibody therapeutics for infectious diseases.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Cancer Support Community provides free psychosocial support, education, and navigation services to cancer patients across all diagnoses. Comparable as a peer cancer-focused patient support nonprofit, though its scope is much broader than CLL/SLL and it lacks CLL-specific medical depth.

TypeDirect peer
Description

Patient Advocate Foundation provides case management, financial aid, and access support to patients with chronic and life-threatening illnesses including cancer. Comparable as a peer patient advocacy nonprofit that provides direct service navigation, though it serves all diagnoses rather than focusing on CLL/SLL.

3American Cancer Society
TypeBroad incumbent
Description

American Cancer Society is the largest US cancer-focused nonprofit, providing patient support, research funding, and advocacy across all cancer types. Comparable as a broad peer in cancer patient support and advocacy, though CLL/SLL represents only a tiny fraction of its program focus.

TypeDirect peer
Description

CLL Global Research Foundation is dedicated exclusively to CLL research funding and global collaboration among CLL investigators. Directly comparable as a CLL-focused nonprofit, though its emphasis is more heavily weighted toward scientific research grants versus patient education and support services.

TypeOthers
Description

NCCN is an alliance of leading cancer centers that publishes the authoritative clinical practice guidelines used by oncologists treating CLL/SLL. Comparable as an adjacent ecosystem stakeholder that shapes the treatment landscape CLL Society educates patients about, though NCCN is provider-facing rather than patient-facing.

6CLL Research Consortium (CRC)
TypeEmerging player
Description

CRC is a multi-institutional research collaboration focused specifically on CLL scientific investigation. Comparable as a CLL-focused research entity, though it operates primarily as a scientific consortium rather than a patient-facing nonprofit with support services.

TypeDirect peer
Description

Lymphoma Research Foundation funds lymphoma-specific research and provides patient education and support, including for SLL. Highly comparable mission, funding model (pharma grants plus individual donations), and program portfolio, though it covers all lymphoma subtypes rather than focusing exclusively on CLL/SLL.

TypeDirect peer
Description

HealthTree Foundation runs a comparable disease-specific nonprofit model for multiple myeloma, with free patient education, peer support, specialist directories, and a clinical trial finder. Operates with a similar digital-first, physician-curated approach and pharma funding base, making it a strong functional peer in adjacent hematologic cancer.

TypeDirect peer
Description

IWMF is a disease-specific patient nonprofit for Waldenstrom macroglobulinemia, a rare B-cell lymphoma closely related to CLL/SLL. Strong functional peer given shared model of patient education, support groups, expert directories, and research funding for a rare hematologic malignancy.

TypeBroad incumbent
Description

LLS is the largest US nonprofit dedicated to blood cancers including leukemia, lymphoma, myeloma, and myelodysplastic syndromes. Directly comparable as a peer disease-advocacy, research-funding, and patient-support organization, though it operates at much greater scale and across all blood cancers rather than CLL/SLL specifically.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CLL Society

Patient Advocacy and Support Servicescllsociety.org

CLL Society is a 501(c)(3) nonprofit founded in 2013 that provides free education, support, advocacy, and research funding for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and their caregivers. Programs include Expert Access virtual second opinions, peer support, treatment decision tools, and a research grant program funded by individual donations and pharmaceutical sponsorships.

What CLL Society does

CLL Society is a 501(c)(3) nonprofit organization founded in 2013 by Dr. Brian Koffman, a physician and CLL patient, and Patricia Koffman, a care partner. Headquartered in Nashville, Tennessee and operating with an 11–50 employee team, the organization provides free education, support, advocacy, and research programs for individuals affected by chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It does not develop commercial technology products; instead it curates physician-reviewed educational content, maintains clinical trial listings, and operates the CLL Medicine Cabinet — a drug information resource covering CLL/SLL therapeutics — alongside a Policy Institute for the immunocompromised community.

The organization's core service offerings include Expert Access™, a free virtual second opinion program delivered through partner Alight's HIPAA-compliant platform connecting US-based patients with world-renowned CLL experts; a Peer Support Program pairing patients one-on-one; CLL-specific support groups; the CareCast podcast; on-demand webinars; the Emotional & Spiritual Advocate Program; the Trusted Care Exchange connecting patients with healthcare providers; and the COVID-19 Resources program for immunocompromised patients. In 2026 the organization launched the CLL Treatment Decision Tool, built with Decera Clinical Education to translate input from five CLL experts into a patient-facing decision aid. The Research Grant Program, launched in 2022 and funded entirely through individual contributions, has cumulatively directed over $2,150,000 to CLL/SLL researchers through Clinical Scholar and Young Investigator Awards.

CLL Society is funded through individual donations and corporate grants/sponsorships from pharmaceutical companies organized into an Industry Advisory Council. The 2026 Council includes Platinum members AbbVie, BeiGene/BeOne, Genentech, and Lilly, and Gold members AstraZeneca and Invivyd. The organization maintains stated editorial independence from corporate donors, does not endorse specific medications, and operates free of charge to patients and caregivers. It has been recognized with a 4-star Charity Navigator rating and a Candid (GuideStar) Platinum Seal of Transparency.

CLL Society firmographics

Firmographics
Name
CLL Society
Legal name
CLL Society Inc.
Website
https://cllsociety.org
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
CLL Society is a 501(c)(3) nonprofit founded in 2013 that provides free education, support, advocacy, and research funding for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and their caregivers. Programs include Expert Access virtual second opinions, peer support, treatment decision tools, and a research grant program funded by individual donations and pharmaceutical sponsorships.
Ownership category
akta.pro rank

Where CLL Society is headquartered

Location

Headquarters

HQ city
Chula Vista
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CLL Society business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Individual Donations: CLL Society is funded primarily through individual donations from patients, caregivers, and supporters of the CLL community. Donations support the organization's mission of education, advocacy, support, and research.
  2. Corporate Grants and Sponsorships: CLL Society receives financial support from pharmaceutical and healthcare companies in the form of restricted and unrestricted grants and sponsorships. The organization maintains full editorial independence and does not endorse specific medications or treatments. Corporate partners include AbbVie, BeiGene/BeOne, Genentech, Lilly, AstraZeneca, and Invivyd through the Industry Advisory Council.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

CLL Society product offering

Product offering

Core offering

CLL Society is a 501(c)(3) nonprofit that provides free education, support, advocacy, and research programs for patients affected by chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Its core offerings include free virtual expert second opinions (Expert Access™), one-on-one peer support, CLL-specific support groups, physician-curated educational content (CareCast Podcast, Education On-Demand webinars, Medicine Cabinet, Patient Education Toolkit), an interactive CLL Treatment Decision Tool, advocacy through its Policy Institute, and a Research Grant Program funding CLL/SLL investigators.

Product overview

CLL Society is a nonprofit patient-centric, physician-curated organization providing comprehensive education, support, and research for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients. The organization offers a suite of patient support services including Expert Access™ (free virtual second opinions), Peer Support Program, Emotional & Spiritual Advocate Program, and CLL-specific support groups. Educational offerings include the CLL Medicine Cabinet (drug information), CLL/SLL Patient Education Toolkit, CareCast Podcast, and Education On-Demand webinars. The CLL Treatment Decision Tool provides algorithmic treatment recommendations based on expert input. CLL Society also funds research through its Research Grant Program and maintains clinical trial information resources.

Differentiator

Problem solved

Functional benefit

Brands

  • Expert Access™: A free virtual second opinion program connecting CLL patients with world-renowned CLL experts.
  • CareCast Podcast
  • Trusted Care Exchange
  • Peer Support Program

Products and services

  • Expert Access™ Free virtual second opinion consultation service connecting CLL/SLL patients in the United States with world-renowned CLL experts via HIPAA-compliant video consultations, producing expert opinions patients can share with their local treatment team.
  • Peer Support Program One-on-one peer support program pairing CLL patients with trained fellow patients for emotional support and shared lived experience.
  • Emotional & Spiritual Advocate Program Program supporting the emotional, spiritual, and mental well-being of CLL patients and their care partners.
  • Support Groups CLL-specific patient support groups providing community connection and peer support for patients and caregivers.
  • CareCast Podcast Educational podcast series providing information and updates on CLL/SLL research, treatments, and patient experiences.
  • Education On-Demand On-demand educational activities and webinars for CLL patients covering treatments, research, and disease management.
  • CLL Medicine Cabinet Comprehensive resource providing detailed information on CLL medications including dosing, side effects, administration, and management guidance.
  • CLL Treatment Decision Tool Interactive treatment decision resource, built with Decera Clinical Education, offering personalized treatment options based on algorithmic inputs from five CLL experts through a patient-completed questionnaire.
  • Research Grant Program Research grant program funding novel projects aimed at improving outcomes and quality of life for CLL/SLL patients, having dedicated $2,150,000 to CLL/SLL researchers since 2022.
  • CLL/SLL Patient Education Toolkit Comprehensive educational resource covering CLL/SLL basics, testing, staging, treatment options, MRD testing, complications, and disease management tools.
  • Trusted Care Exchange Resource connecting CLL patients with healthcare providers and facilitating care coordination.
  • COVID-19 Resources COVID-19 information and resources specific to CLL/SLL patients, including action plans, prevention, treatment guidance, and virtual community meetings.

Companies that use CLL Society

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles4 records

CLL Society technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

CLL Society partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • AlightcoreStrategic or Co-development PartnerCLL Society partners with Alight, an online second opinion service that uses live video technology to connect patients with top US-based medical specialists. Alight provides HIPAA-compliant platform infrastructure for the Expert Access program's virtual consultations. Eighty percent of those provided a 2nd opinion through Alight were seeking oncology consultations.
  • Decera Clinical EducationcoreStrategic or Co-development PartnerCLL Society collaborated with Decera Clinical Education to create the CLL Treatment Decision Tool, offering information about common treatment options for CLL. Decera's mission is to improve clinical care and patient health outcomes through evidence-based educational activities.
  • AbbVie (Platinum Industry Advisory Council)minorGTM or Marketing PartnerPlatinum member of CLL Society's 2026 Industry Advisory Council. AbbVie manufactures Imbruvica (ibrutinib) and venetoclax (Venclexta) used in CLL treatment.
  • BeiGene/BeOne (Platinum Industry Advisory Council)minorGTM or Marketing PartnerPlatinum member of CLL Society's 2026 Industry Advisory Council. BeiGene manufactures zanubrutinib (Brukinsa) and sonrotoclax (Beqalzi) used in CLL treatment.
  • Genentech (Platinum Industry Advisory Council)minorGTM or Marketing PartnerPlatinum member of CLL Society's 2026 Industry Advisory Council. Genentech manufactures obinutuzumab (Gazyva) used in CLL treatment.
  • Lilly (Platinum Industry Advisory Council)minorGTM or Marketing PartnerPlatinum member of CLL Society's 2026 Industry Advisory Council.
  • AstraZeneca (Gold Industry Advisory Council)minorGTM or Marketing PartnerGold member of CLL Society's 2026 Industry Advisory Council. AstraZeneca manufactures acalabrutinib (Calquence) used in CLL treatment.
  • Invivyd (Gold Industry Advisory Council)minorGTM or Marketing PartnerGold member of CLL Society's 2026 Industry Advisory Council. Invivyd focuses on antibody therapeutics for infectious diseases.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

CLL Society competitors and assessment

Company assessment

Broad incumbents

  • Cancer Support Community: Cancer Support Community provides free psychosocial support, education, and navigation services to cancer patients across all diagnoses. Comparable as a peer cancer-focused patient support nonprofit, though its scope is much broader than CLL/SLL and it lacks CLL-specific medical depth.
  • American Cancer Society: American Cancer Society is the largest US cancer-focused nonprofit, providing patient support, research funding, and advocacy across all cancer types. Comparable as a broad peer in cancer patient support and advocacy, though CLL/SLL represents only a tiny fraction of its program focus.
  • The Leukemia & Lymphoma Society (LLS): LLS is the largest US nonprofit dedicated to blood cancers including leukemia, lymphoma, myeloma, and myelodysplastic syndromes. Directly comparable as a peer disease-advocacy, research-funding, and patient-support organization, though it operates at much greater scale and across all blood cancers rather than CLL/SLL specifically.

Direct peers

  • Patient Advocate Foundation: Patient Advocate Foundation provides case management, financial aid, and access support to patients with chronic and life-threatening illnesses including cancer. Comparable as a peer patient advocacy nonprofit that provides direct service navigation, though it serves all diagnoses rather than focusing on CLL/SLL.
  • CLL Global Research Foundation: CLL Global Research Foundation is dedicated exclusively to CLL research funding and global collaboration among CLL investigators. Directly comparable as a CLL-focused nonprofit, though its emphasis is more heavily weighted toward scientific research grants versus patient education and support services.
  • Lymphoma Research Foundation: Lymphoma Research Foundation funds lymphoma-specific research and provides patient education and support, including for SLL. Highly comparable mission, funding model (pharma grants plus individual donations), and program portfolio, though it covers all lymphoma subtypes rather than focusing exclusively on CLL/SLL.
  • HealthTree Foundation for Multiple Myeloma: HealthTree Foundation runs a comparable disease-specific nonprofit model for multiple myeloma, with free patient education, peer support, specialist directories, and a clinical trial finder. Operates with a similar digital-first, physician-curated approach and pharma funding base, making it a strong functional peer in adjacent hematologic cancer.
  • International Waldenstrom's Macroglobulinemia Foundation (IWMF): IWMF is a disease-specific patient nonprofit for Waldenstrom macroglobulinemia, a rare B-cell lymphoma closely related to CLL/SLL. Strong functional peer given shared model of patient education, support groups, expert directories, and research funding for a rare hematologic malignancy.

Others

  • National Comprehensive Cancer Network (NCCN): NCCN is an alliance of leading cancer centers that publishes the authoritative clinical practice guidelines used by oncologists treating CLL/SLL. Comparable as an adjacent ecosystem stakeholder that shapes the treatment landscape CLL Society educates patients about, though NCCN is provider-facing rather than patient-facing.

Emerging players

  • CLL Research Consortium (CRC): CRC is a multi-institutional research collaboration focused specifically on CLL scientific investigation. Comparable as a CLL-focused research entity, though it operates primarily as a scientific consortium rather than a patient-facing nonprofit with support services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

CLL Society social profiles

Digital presence

CLL Society compliance and trust

Trust signal

Compliance3 records

CLL Society financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CLL Society leadership team

Management profile

Number of profiles

Profiles2 records

CLL Society funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CLL Society M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CLL Society

What does CLL Society do?

CLL Society is a 501(c)(3) nonprofit that provides free education, support, advocacy, and research programs for patients affected by chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Its core offerings include free virtual expert second opinions (Expert Access™), one-on-one peer support, CLL-specific support groups, physician-curated educational content (CareCast Podcast, Education On-Demand webinars, Medicine Cabinet, Patient Education Toolkit), an interactive CLL Treatment Decision Tool, advocacy through its Policy Institute, and a Research Grant Program funding CLL/SLL investigators.

Is CLL Society a public or private company?

CLL Society is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was CLL Society founded?

CLL Society was founded in 2013. It employs 11 to 50 people.

Where is CLL Society based?

CLL Society is headquartered in Chula Vista, United States, in the North America region.

How does CLL Society make money?

Two revenue lines are on record. Individual Donations are the primary driver. The others are corporate Grants and Sponsorships.

Who are CLL Society's main competitors?

Broad incumbents on record are Cancer Support Community, American Cancer Society and The Leukemia & Lymphoma Society (LLS). Direct peers are Patient Advocate Foundation, CLL Global Research Foundation, Lymphoma Research Foundation, HealthTree Foundation for Multiple Myeloma and International Waldenstrom's Macroglobulinemia Foundation (IWMF). National Comprehensive Cancer Network (NCCN) is listed as an others. CLL Research Consortium (CRC) is listed as an emerging player.

Does CLL Society have an API?

No public API is recorded for CLL Society.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerCLL Society And BeOne Medicines Announce Expanded Partnership To Advance Education And Support Across The CLL/SLL CommunityCLL Society and BeOne Medicines announced a three-year partnership to expand education and support for the CLL/SLL community. The partnership provides $3 million to advance initiatives including biomarker testing education, digital resources, and community engagement programs.Business Wire BlogCLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL CommunityCLL Society and BeOne Medicines announced an expanded three-year partnership to advance education and support for CLL/SLL patients and providers. BeOne's funding increases to $3 million, supporting initiatives like biomarker testing education and AI-enabled digital resources. The partnership aims to help patients make informed treatment decisions.Stock TitanBeOne Medicines lifts CLL Society support to $3MBeOne Medicines and CLL Society announced an expanded three-year partnership to advance education and support for CLL/SLL patients and providers. The partnership expands BeOne's support to $3 million, including initiatives like biomarker testing education and AI-enabled digital resources.TradingViewCLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL CommunityCLL Society and BeOne Medicines announced an expanded three-year partnership to advance education and support for CLL/SLL patients. The partnership increases funding to $3 million, supporting initiatives like biomarker testing education and AI-enabled digital resources. The collaboration aims to help patients navigate complex treatment landscapes.FiercePharmaBeOne commits $3M to expand CLL Society patient education partnershipBeOne Medicines expanded its partnership with CLL Society, signing a three-year, $3 million pact to support leukemia and lymphoma patients. The funding will support education, digital resources, and an AI-enabled search tool, building on a 2024 collaboration for biomarker testing.PrwebCLL Society Appoints Physician-Scientist Kirk Taylor, MD, as Chief Medical Officer to Lead Its Next Stage of GrowthCLL Society appointed Kirk Taylor, MD, as Chief Medical Officer, succeeding co-founder Brian Koffman. Taylor brings over 25 years in drug development and medical affairs, including experience with CLL therapies. He will lead medical integrity for new physician-curated information.PR.comCLL Society to Present Innovative Telemedicine Platform Study at American Society of Hematology Annual Conference - PR.comThe CLL Society will present its Expert Access telemedicine program at the American Society of Hematology annual meeting in December. Since 2017, the program provided 158 free visits, with 75% of patients planning care changes and 95% citing convenience as important.PrwebEnrollment for Expert Access, a No-Cost Second Opinion Program by the CLL Society and Powered by InfiniteMD, Now OpenThe CLL Society and InfiniteMD opened enrollment for the 2019 Expert Access program, a no-cost second opinion service for CLL patients. Capacity expanded by 25% to 150 consultations, up from 120 in 2018. Enrollment is first-come-first-served for U.S. patients.